Sema4’s latest DNA screening test is a typical precedent underlining the advancements across prenatal & new-born genetic testing market. Recently launched, this pioneering DNA screening test, dubbed as Sema4 Natalis, is particularly designed to detect nearly 193 childhood onset genetic diseases, using highly advanced next generation DNA sequencing. Reportedly, the test would be also including a complete pharmacogenetic analysis of how a newborn is likely to respond to the 38 medications that are commonly prescribed. Indeed, this supplemental newborn screening test is touted to be one of the most futuristic ones of its kind to have been released in prenatal and new-born genetic testing market , especially against a backdrop where nearly 7.9 million infants globally are detected with birth defects. —
The United States: One of the top-notch growth avenues for prenatal and new-born genetic testing market
Newborn and prenatal screening was actually initiated due to its potential to prevent severe genetic disabilities. In fact, according to latest report, currently more than 98% of the 4 million newborns in the United States undergo genetic screening annually for over 30 treatable genetic, endocrine, infectious, and metabolic diseases within first week of their birth. Not to mention, this has left a remunerative impact on U.S. prenatal and new-born genetic testing market, which pegged a valuation of approximately USD 2 billion in 2017.
Request sample copy of this report @ https://www.gminsights.com/request-sample/detail/1906
It is therefore irrefutable that the underlining principle that lurks behind the introduction of groundbreaking solutions in prenatal and new-born genetic testing industry is the dire necessity of reducing mortality and morbidity rate in infants having inherent genetic disorders. Experts claim that identifying the heritable conditions at early stage can improve a child’s long-term health and survival. However, as it has been observed, the number and type of genetic disorders that are included in newborn screening vary geographically. Say for instance, presently there are 34 core hereditary conditions and 26 secondary conditions that are recommended by the United States Department of Health and Human Services for newborn screening. Thus, it can be inferred that administrative backup is a major factor influencing prenatal and new-born genetic testing industry outlook.
How advancements in prenatal diagnosis is impacting the overall industry trend?
Corresponding to the continuous intervention of technological advancements, the present practice of prenatal screening, i.e. testing genetic abnormalities even in the fetus, has undergone a dramatic transformation of sorts. Non-invasive cell-free DNA screening for fetal aneuploidy, whole-exome sequencing, chromosomal microarray analysis, and screening for subchromosomal abnormalities, have indeed sent out waves of anticipation in prenatal and newborn screening market. Enlisted below are some of the latest initiatives encompassing this particular business vertical, expected to leave a palpable impact on the overall industry share over the coming years.
Make Inquiry about this report @ https://www.gminsights.com/inquiry-before-buying/1906
LifeCell, one of the leading names in India prenatal and new-born genetic testing market, has recently launched ‘Pentastic’ – a prenatal test designed to detect genetic abnormalities in fetus. Allegedly, this ultrasound biochemistry-based blood test is recommended for would be mothers in the first trimester of pregnancy i.e., between 11 to 13 weeks. As claimed by experts, Pentastic test is likely to gain an advantage over other conventional prenatal screening, as it incorporates five analytes (PAPP-A + free hCGß + AFP + Inhibin-A + PIGF), against its contemporaries which include only two analytes. Experts have been already raving about the technology claiming it to prominently disrupt the prenatal and new-born genetic testing industry product terrain.
Renowned American molecular diagnostics company Myriad Genetics has recently made to the headlines with its acquisition of Counsyl. The USD 375 million worth deal, reportedly is a strategic move by former to strengthen its portfolio in the rapidly evolving prenatal and newborn genetic testing market with Counsyl’s Prelude test portfolio. Through the alliance, Myriad Genetics would be merging Counsyl’s extensive reproductive health tests and existing preventive care business into a new unit, dubbed as Myriad Women’s Health. For the records, this new unit would be solely focusing on reproductive healthcare providers and OB-Gyns.
It is imperative to mention that the unprecedented advancements in genomic medicine are critically impacting prenatal diagnosis, subsequently boosting prenatal and new-born genetic testing industry size. Of course, the full potential of the business space can only be realized if these groundbreaking innovations are introduced in a substantiation-based ethically responsible manner and securitized after implementation. However, with genetic abnormalities and chromosomal disorders in infants becoming a global concern, prenatal and new-born genetic testing industry, in all likelihood, would reach remarkable stature in terms of innovations and revenue. Global Market Insights, Inc. forecasts the overall business space to exceed a valuation of USD 7 billion by 2024.
Chapter 1. Methodology
1.1.1. Initial data exploration
1.1.2. Statistical model and forecast
1.1.3. Industry insights and validation
1.1.4. Market definition and forecast parameters
1.2. Data sources
Chapter 2. Executive Summary
2.1. Prenatal and newborn genetic testing industry 3600 synopsis, 2013 - 2024
2.1.1. Business trends
2.1.2. Technology trends
2.1.3. Disease trends
2.1.4. End-use trends
2.1.5. Regional trends
Chapter 3. Prenatal and New-born Genetic Testing Market Industry Insights
3.1. Industry segmentation
3.2. Industry landscape, 2013 – 2024
3.3. Industry impact forces
3.3.1. Growth drivers
220.127.116.11. Technological advancements and increasing benefits in the field of prenatal testing and newborn genetic screening in North America
18.104.22.168. Increasing prevalence of genetic disorders and chromosomal abnormalities in Europe
22.214.171.124. Rising consanguineous relations in countries of APAC and Middle east and Africa
126.96.36.199. Government initiatives and support for prenatal testing and newborn genetic screening in Asia-Pacific
188.8.131.52. Rise in adoption of Noninvasive Prenatal Testing in Latin America
3.3.2. Industry pitfalls & challenges
184.108.40.206. Increasing false results for prenatal tests in Europe
220.127.116.11. Lack of advanced infrastructure and skilled labor in developing region of Latin America and Asia-Pacific
18.104.22.168. Ethical issues to prenatal testing and newborn genetic screening in Asia-Pacific and Middle East and Africa
3.4. Growth potential analysis
3.4.1. By technology
3.4.2. By disease
3.4.3. By end-use
3.5. Regulatory landscape
3.6. Porter’s analysis
3.7. Competitive landscape, 2017
3.7.1. Business overview
3.7.2. Revenue analysis
3.7.3. Product landscape
3.7.4. Strategy dashboard
3.8. PESTEL analysis
Release ID: 88929526